Abstract
Background Despite its significant heritability, the genetic underpinnings of Parkinson disease (PD) remain incompletely understood, particularly the role of rare variants. Advances in population-scale sequencing now provide an unprecedented opportunity to uncover additional large-effect rare genetic risk factors and expand our understanding of disease mechanisms.
Methods We leveraged whole-genome sequence data with linked electronic health records from 490,560 UK Biobank participants, identifying 3,809 PD cases and 247,101 controls without a neurological disorder. We performed both variant-and gene-level association analyses to identify novel genetic associations with PD. We analyzed two additional independent case-control cohorts for replication (totaling 3,739 cases and 58,156 controls). Additionally, we performed functional validation of a novel PD association in a human synuclein-expressing Drosophila model.
Findings In the UK Biobank, we replicated associations in well-established loci including GBA1 and LRRK2. We also identified a novel association between protein-truncating variants (PTVs) in ITSN1 and an increased risk of PD, with an effect size exceeding those of established loci (Fisher’s Exact Test: p=6.1x10-7; Odds ratio [95% confidence interval] = 10.53 [5.20, 21.34]). We replicated the ITSN1 risk signal in a meta-analysis across all cohorts (Cochran-Mantel-Haenszel test p=5.7x10-9; Odds ratio [95% confidence interval] = 9.20 [4.66, 16.70]). In Drosophila, haploinsufficiency of the ITSN1 ortholog (Dap160) exacerbated α-synuclein-induced compound eye degeneration and motor deficits.
Interpretation We establish ITSN1 as a novel risk gene for PD, with PTVs substantially increasing disease risk. ITSN1 encodes a scaffold protein involved in synaptic vesicle endocytosis, a critical pathway increasingly recognized in PD pathogenesis. Our findings highlight the power of large-scale sequencing coupled with preclinical functional modeling to identify rare variant associations and elucidate disease mechanisms.
Competing Interest Statement
T.P.S., J.M., F.H., Q.W., D.V., M.G., M.M., G.D.A., B.H., S.P., and I.T. are current employees and/or shareholders of AstraZeneca. R.S.D. is a paid consultant of AstraZeneca. H.Y.Z. is a member of the Regeneron Pharmaceuticals Board of Directors, co-founder of Cajal Neuroscience, and on the science advisory board of the Column group.
Funding Statement
R.S.D. is supported by NIH DP5 OD036131 and a Longevity Impetus Grant from Norn Group, Hevolution Foundation, and Rosenkranz Foundation. J.C.B., Y.K., and H.Y.Z. received support from Howard Hughes Medical Institute. Y.K., H.Y.Z., and J.S. received support from the Huffington Foundation. Fruit fly work was performed at the Neurobehavioral Core at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY human data publicly available to registered researchers located within the UK Biobank (http://www.ukbiobank.ac.uk/register-apply/), 100KGP (https://www.genomicsengland.co.uk/research/academic), AMP-PD (https://amp-pd.org), and All of Us (https://www.researchallofus.org/data-tools/workbench/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated the formatting of the online version of the abstract, and fixed references on page 15.
